



January 5, 2026

Company:	KYORIN Pharmaceutical Co., Ltd.
Representative:	Yutaka Ogihara Representative Director, President and CEO (Security Code: 4569, TSE Prime.)
Contact:	Shota Kikuchi Director, Corporate Planning
Telephone:	03-6374-9702

KYORIN and Lunatus Enter into Distribution Agreement for Lasvic® Tablets in Nine Middle Eastern Countries

KYORIN Pharmaceutical Co., Ltd. announced today that it has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO (President and CEO: Dr Lina Kouatly “Lunatus”) on January 5, 2026, for Lasvic tablets (Lascufloxacin hydrochloride, “Product”).

Under the terms of this agreement, Lunatus will be the exclusive partner of the Product in Saudi Arabia, the UAE, Kuwait, Bahrain, Qatar, Oman, Iraq, Lebanon, and Jordan, and KYORIN will register as the Marketing Authorization Holder (MAH) in each country and supply the Product to Lunatus.

The Product is an oral fluoroquinolone antibacterial agent developed by KYORIN for respiratory and otorhinolaryngology (ear, nose, and throat: ENT) infections. It is designed to concentrate effectively in lung and ENT tissues while maintaining low systemic exposure, providing potent antibacterial activity at the site of infection.

In our medium-term business plan, "Vision 110 – Stage 1 –", KYORIN is proactively pursuing out-licensing activities to maximize the value of KYORIN's proprietary products. Through this partnership with Lunatus, KYORIN aims to make the Product widely available across the Middle East and continue our mission of contributing to people's health.

The impact on business performance for the fiscal year ending March 2026 is to be negligible.

[Reference]

About Lunatus Marketing & Consulting FZCO

Established in 2003, Lunatus is a market-leading Turn-key solutions provider for international pharmaceutical and healthcare companies, offering end-to-end support spanning regulatory, marketing, sales, distribution, and supply chain to build and scale strong brand presence in the region. Active across the Arabian Gulf countries and the broader Middle East, Lunatus enables successful launches and sustainable double-digit growth. Since 2022, Marubeni has invested in Lunatus to deepen Japan–Middle East collaboration and accelerate the introduction of high-quality Japanese pharmaceuticals and medical devices throughout the region.

For more information, please visit <https://lunatus.com>

About Lasvic tablets

Lasvic is an oral fluoroquinolone antibacterial agent for respiratory and ENT infections. It is designed to concentrate effectively in the lungs and ENT tissues while maintaining low systemic exposure, providing potent antibacterial activity at the site of infection. Lasvic shows favorable activity against *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Mycoplasma pneumoniae*, oral *streptococci* and anaerobes, which are mentioned as pathogens detected in community-acquired pneumonia (CAP), as noted in clinical guidelines*.

*The JRS Guideline for the Management of Pneumonia in Adults 2024

This document is for reference purposes only. In case of any discrepancy, the Japanese version shall prevail.